National Medical Products Administration (NMPA)
Is Maridebart cafraglutide (MariTide) legal in China?
Not approvedNot approved in China; Amgen has trial-stage filings and Chinese sites in its outcomes trial.
Not approved as a medicine here.
CDE's public register shows Amgen import clinical-trial applications for AMG 133 (maridebart cafraglutide) accepted on 2026-07-13. Amgen's cardiovascular outcomes trial lists 40 sites in China. No marketing application was found, so the drug cannot lawfully be sold as a medicine in China.
Last verified 2026-09-29 · how we verify
Maridebart cafraglutide (MariTide) elsewhere
Sources (3)
- 01CDE public register of accepted drug applications (受理品种目录浏览)Center for Drug Evaluation (CDE), NMPA · 2026-09-29 · accessed 2026-09-29
- 02Evaluating the impact of maridebart cafraglutide on cardiovascular outcomes in participants with atherosclerotic cardiovascular disease and obesity (NCT07037433)U.S. National Library of Medicine (ClinicalTrials.gov) · 2025-07 · accessed 2026-09-29
- 03Drug Administration Law of the PRC (中华人民共和国药品管理法)National Medical Products Administration (NMPA) · 2019-08-26 · accessed 2026-09-29